BRIT J CANCER 2019 10.1038/s41416-019-0618-z
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
Sim1, SH; Park, IH; Jung, KH; Kim, SB; Ahn, JH; Lee, KH; Im, SA; Im, YH; Park, YH; Sohn, J; Kim, YJ; Lee, S; Kim, HJ; Chae, YS; Park, KH; Nam, BH; Lee, KS; Ro, J

LANCET ONCOL 2019 10.1016/S1470-2045(19)30565-0
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Park1, YH; Kim, TY; Kim, GM; Kang, SY; Park, IH; Kim, JH; Lee, KE; Ahn, HK; Lee, MH; Kim, HJ; Kim, HJ; Lee, JI; Koh, SJ; Kim, JY; Lee, KH; Sohn, J; Kim, SB; Ahn, JS; Im, YH; Jung, KH; Im, SA

KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.226
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
Heo1, MH; Kim, HK; Lee, H; Kim, JY; Ahn, JS; Im, YH; Park, YH

CANCER 2019 10.1002/cncr.32392
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE
Perez1, EA; Barrios, C; Eiermann, W; Toi, M; Im, YH; Conte, P; Martin, M; Pienkowski, T; Pivot, XB; Burris, HA; Petersen, JA; De Haas, S; Hoersch, S; Patre, M; Ellis, PA

CANCER COMMUN 2019 10.1186/s40880-019-0375-7
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
Kim1, JY; Park, S; Im, SA; Kim, SB; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH; Park, YH

BMC CANCER 2019 10.1186/s12885-019-5687-0
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Perez1, EA; de Haas, SL; Eiermann, W; Barrios, CH; Toi, M; Im, YH; Conte, PF; Martin, M; Pienkowski, T; Pivot, XB; Burris, HA; Stanzel, S; Patre, M; Ellis, PA

CANCER RES TREAT 2019 10.4143/crt.2018.262
Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
Kim1, EK; Cho, J; Kim, JY; Chang, SA; Park, SJ; Choi, JO; Lee, SC; Ahn, JS; Park, SW; Im, YH; Jeon, ES; Park, YF

CANCER RES TREAT 2019 10.4143/crt.2018.342
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Kim1, HK; Park, KH; Kim, Y; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Lee, JE; Ahn, JS; Im, YH; Yu, JH; Park, YH

ONCOLOGIST 2019 10.1634/theoncologist.2018-0184
Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
Kang1, D; Kim, IR; Choi, EK; Im, YH; Park, YH; Ahn, JS; Lee, JE; Nam, SJ; Lee, HK; Park, JH; Lee, DY; Lacouture, ME; Guallar, E; Cho, J

SCI REP-UK 2019 10.1038/s41598-019-41098-0
Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator
Oh1, BY; Shin, HT; Yun, JW; Kim, KT; Kim, J; Bae, JS; Cho, YB; Lee, WY; Yun, SH; Park, YA; Park, YH; Im, YH; Lee, J; Joung, JG; Kim, HC; Park, WY

ONCOL LETT 2019 10.3892/ol.2018.9754
Clinical features and prognosis of breast cancer with gastric metastasis
Hong1, J; Kim, Y; Cho, J; Lim, SW; Park, SE; Kim, HK; Lee, H; Cho, SY; Kim, JY; Ahn, JS; Im, YH; Park, YH

BMC CANCER 2019 10.1186/s12885-018-5258-9
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
Kim1, HK; Lee, SH; Kim, YJ; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Ahn, JS; Im, YH; Yu, JH; Park, YH

BREAST CANCER RES TR 2019 10.1007/s10549-018-4981-x
A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients
Hwang1, HW; Jung, H; Hyeon, J; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Choi, M; Cho, SY; Cho, EY

HERED CANCER CLIN PR 2019 10.1186/s13053-018-0103-3
The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans
Kim1, H; Choi, DH; Park, W; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Jung, BY

J BREAST CANC 2018 10.4048/jbc.2018.21.e48
PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis
Seo1, Y; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Cho, SY; Cho, EY

INT J CANCER 2018 10.1002/ijc.31651
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
Park1, YH; Lee, KH; Sohn, JH; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Ahn, JS; Kim, TY; Kim, GM; Park, IH; Kim, SB; Kim, SH; Han, HS; Im, YH; Ahn, JH; Kim, JY; Kang, J; Im, SA

EUR J CANCER 2018 10.1016/j.ejca.2018.08.004
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
Kim1, JY; Im, SA; Jung, KH; Ro, J; Sohn, J; Kim, JH; Park, YH; Kim, TY; Kim, SB; Lee, KS; Kim, GM; Kim, SH; Kim, S; Ahn, JS; Lee, KH; Ahn, JH; Park, IH; Im, YH

CLIN BREAST CANCER 2018 10.1016/j.clbc.2018.04.010
Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment
Cho1, WK; Choi, DH; Park, W; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY; Ahn, S

BREAST CANCER RES TR 2018 10.1007/s10549-018-4858-z
Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort
Kim1, JY; Lim, JE; Jung, HH; Cho, SY; Cho, EY; Lee, SK; Yu, JH; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH

ANN ONCOL 2018 10.1093/annonc/mdy257
Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial
Ettl1, J; Quek, RGW; Lee, KH; Rugo, HS; Hurvitz, S; Goncalves, A; Fehrenbacher, L; Yerushalmi, R; Mina, LA; Martin, M; Roche, H; Im, YH; Markova, D; Bhattacharyya, H; Hannah, AL; Eiermann, W; Blum, JL; Litton, JK